Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
Discover More Information about Blood Group Antigens on Erythrocyte Cell Surfaces
Glycolipids are composed of carbohydrate complexes and have the natural ability to insert into red blood cell membranes. It is anchored to the outer lipid membrane of erythrocytes via their dual lipid tails. Glycolipids have the natural ability to insert into red blood cell membranes. Based on De Novo Glycan Display, CD BioGlyco has developed a series of synthetic glycolipids for modifying erythrocytes. These synthetic glycolipids are determinants in the expression of carbohydrate blood groups. Furthermore, we change the blood group antigens (O-, A-, and B-type antigens) to analyze the changes in the red blood cell surface.
Fig.1 Schematic diagrams of a natural blood group glycolipid. (Frame, et al., 2007)
In immune responses, blood group antigens play a key role at the cell membrane. Thus, systematic analysis of changes in cell surface antigens is highly essential. At CD BioGlyco, we mainly provide these services:
- Synthetic glycolipid modification of red blood cells
- Our professional synthesis team helps clients customize the synthesis of glycolipid. We provide molecular structure design, synthesis and characterization, and bioactivity validation services.
- We co-incubate synthetic glycolipids containing different antigen types with O-type red blood cells to insert glycolipids into the cell membranes. After incubation, the modified cells are washed several times. We examine the diluted concentration of synthetic glycolipids in solution and provide antigen expression detection services in cells.
- Serologic testing and fluorescein red blood cells
- Our investigators use multiple monoclonal antibodies to evaluate the modified cells. We provide services for red blood cell agglutination experiments, complement binding experiments, protein detection, and enzyme-linked immunosorbent test (ELISA) with luminescent substances and fluorescein labels. In addition, we also provide immunohistochemistry, co-immunoprecipitation, and immunological imprinting services.
- Convert blood group
- We provide other immunogenic removal services to transform blood groups including enzymatic therapy, gene editing, and chemical modification.
Fig.2 Schematic diagram of altering blood group antigens on erythrocyte cell surfaces. (CD BioGlyco)
Publication
Paper Title: Synthetic glycolipid modification of red blood cell membranes
Technology: Serologic testing, Fluorescein modification, Fluorescence microscope
Journal: Transfusion
Published: 2007
Results: In this study, blood group glycolipid analogs A and B were synthesized and successfully inserted on the surface of red blood cells (RBC). These synthetic molecules stabilize and modify the cell surface through carbohydrate blood group antigens. The analytical results showed that the modified cells successfully displayed artificial glycolipids A and B, and detected strong immune specificity in both anti-A and anti-B antibodies. In summary, erythrocytes can be directional expression by the insertion of synthetic glycolipids.
Fig.3 RBCs stained with SYN-fluorescein show an even distribution of SYN molecules in the cell membrane. (Frame, et al., 2007)
Applications of Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Regulating and reorganizing the architecture of cell-surface glycolipids provides a powerful tool for elucidating the molecular mechanisms underlying cell membrane-mediated signaling events and their downstream cellular consequences.
- Modified red blood cells can be used in transfusion medical research and are new targets for selective development and research of cell surface engineering.
- Antigen-protected red blood cells maintain the normal physiological structure and function of the original red blood cells. Antigen-protected red blood cells avoid agglutination caused by blood group mismatch, and thus effectively replace RBCs in the case of RBCs with insufficient blood supply.
Advantages of Us
- Our operators strictly control the time and temperature of incubation to ensure providing high-quality service.
- We have a professional Glycan Display Platform to provide clients with comprehensive and highly efficient services.
CD BioGlyco has an experienced talent team for our clients with comprehensive de novo glycan display services. De novo glycan display has a key role in controlling biological responses. Please feel free to contact us for more details.
References
- Frame, T.; et al. Synthetic glycolipid modification of red blood cell membranes. Transfusion. 2007, 47(5): 876-82.
- Griffin, M.E.; Hsieh-Wilson, L.C. Glycan engineering for cell and developmental biology. Cell Chem Biol. 2016, 23(1): 108-121.
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




